Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.

Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with ...

The FDA has accepted for review a new drug application (NDA) for UGN-103, an investigational intravesical formulation of ...

The FDA has granted accelerated approval to dostarlimab (Jemperli) for adults with stage II or III locally advanced rectal ...

Ryan Moore, MD, discusses the choice between surgery and total neoadjuvant therapy (TNT) for rectal cancer and when watch-and ...

SABR improved recurrence-free survival vs historical benchmark with IVC tumor thrombus; investigators hypothesize this could ...

Selpercatinib (Retevmo), a selective oral RET inhibitor, demonstrated durable antitumor activity and a manageable safety ...

Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...

Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether ...

Ashley Rosko, MD, discusses how telehealth can improve access to myeloma transplant evaluation, reduce care disparities, and ...

Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate ...

Platinum/etoposide regimens carry an intermediate risk of febrile neutropenia in extensive-stage small cell lung cancer ...